Literature DB >> 18005205

An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.

Man-Kay Li1, Lester Garcia, Nelson Patron, Lei Chang Moh, Murali Sundram, Somboon Leungwattanakij, Choosak Pripatnanont, Christopher Cheng, Man Chi-Wai, Ngai Loi-Cheong.   

Abstract

OBJECTIVE: To examine the characteristics, management practices and outcomes of patients presenting with symptoms of benign prostatic hyperplasia (BPH) in Asia, with a focus on comorbidities and sexuality. PATIENTS AND METHODS: In this multinational prospective observational registry, eligible patients with BPH attending a urology clinic for the first time were enrolled. Details of comorbidities, sexuality and symptoms of BPH were collected through the International Prostate Symptom Score (IPSS), International Index of Erectile Dysfunction-5 (IIEF-5) and the Danish Prostate Symptom Score (DAN-PSS-1) questionnaires. The follow-up was scheduled at 1-3 or 3-6 months, depending on the treatment.
RESULTS: In 994 men aged 40-88 years the most common comorbidities were hypertension (38%) and obesity (36%). Nocturia was the most common symptom for consultation. A previous episode of acute urinary retention (AUR) was recorded in 12%. About 90% of the men had moderate-to-severe lower urinary tract symptoms (LUTS), and the severity increased with age. Sexual dysfunction was reported by 82%, and it correlated with the severity of LUTS. Of 918 sexually active men, only 20% had normal erectile function; 36%, 19% and 25% reported severe, moderate and mild erectile dysfunction (ED), respectively. BPH medication was started in 78%, 9% had surgery, and in 13% an approach of watchful waiting was adopted. In all, 89% of patients completed the follow-up. The symptoms of BPH resolved in 93% after surgery, in 83% on BPH medication and in 34% of those on 'watchful waiting'. Surgery, which led to a mean reduction of 17.0 IPSS points, was the most effective in improving LUTS. Improvement on the DAN-PSS-1 items of reduced erection and reduced ejaculation was higher with medication, while surgery led to better outcomes on the DAN-PSS-1 item of pain/discomfort on ejaculation. For ED, from baseline to after treatment, the mean IIEF-5 scores changed from 19.1 to 18, from 14.2 to 14.8, and from 4.5 to 5.5 for those with mild, moderate and severe ED at baseline, respectively. Only 2.3% of patients had an episode of AUR while on treatment. About 5.5% of patients on BPH medication and 6% of surgical patients reported adverse events.
CONCLUSION: Asian patients with BPH usually present with LUTS; sexual dysfunction is also very common. BPH medication is the most frequent treatment approach, followed by watchful waiting and surgery. Medication and surgery resulted in a greater reduction of LUTS and improvement in sexual dysfunction than watchful waiting. As Asian men remain sexually active even at advanced ages, sexual function should be assessed and discussed with the patient before deciding the management strategy for LUTS associated with BPH.

Entities:  

Mesh:

Year:  2007        PMID: 18005205     DOI: 10.1111/j.1464-410X.2007.07320.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

2.  An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Zhe Jin; Zhi-Chao Zhang; Ji-Hong Liu; Jun Lu; Yu-Xin Tang; Xiang-Zhou Sun; Wei-Dong Song; Bing Gao; Ying-Lu Guo; Zhong-Cheng Xin
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

Review 3.  The Effect of LUTS/BPH and Treatments on Ejaculatory Function.

Authors:  Michelle Herberts; Michael Butcher; Tobias Köhler
Journal:  Curr Urol Rep       Date:  2016-07       Impact factor: 3.092

Review 4.  Marijuana, Alcohol, and ED: Correlations with LUTS/BPH.

Authors:  Granville L Lloyd; Brett Wiesen; Mike Atwell; Anna Malykhina
Journal:  Curr Urol Rep       Date:  2021-02-08       Impact factor: 3.092

5.  Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group".

Authors:  Peter Weibl; Tobias Klatte; Peter Laurinc; Roman Tomaškin; Shahrokh F Shariat; Miroslav Helbich; Danica Fackovcova; Peter Bujdák
Journal:  Wien Klin Wochenschr       Date:  2014-12-02       Impact factor: 1.704

Review 6.  Measurement of benign prostatic hyperplasia treatment effects on male sexual function.

Authors:  T A Skolarus; J T Wei
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

7.  Predictors of self-reported benign prostatic hyperplasia in European men: analysis of the European National Health and Wellness Survey.

Authors:  Shonda A Foster; Emily F Shortridge; Marco DiBonaventura; Lars Viktrup
Journal:  World J Urol       Date:  2014-08-07       Impact factor: 4.226

8.  A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men.

Authors:  Raouf Seyam
Journal:  Ther Adv Urol       Date:  2013-10

9.  Selective spinal anesthesia using 1 mg of bupivacaine with opioid in elderly patients for transurethral resection of prostate.

Authors:  Na Young Kim; So Yeon Kim; Hyang Mi Ju; Hae Keum Kil
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

10.  Retrospective analysis of the changes in the surgical treatment of benign prostatic hyperplasia during an 11-year period: a single-center experience.

Authors:  Zhu-Feng Peng; Jing Zhou; Pan Song; Lu-Chen Yang; Bo Yang; Zheng-Ju Ren; Lin-Chun Wang; Qiang Wei; Qiang Dong
Journal:  Asian J Androl       Date:  2021 May-Jun       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.